Recent Investment Analysts’ Ratings Changes for Alkermes (ALKS)

Alkermes (NASDAQ: ALKS) recently received a number of ratings updates from brokerages and research firms:

• 12/22/2025 – Alkermes was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating.
• 12/16/2025 – Alkermes had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/10/2025 – Alkermes had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – Alkermes was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b-)” rating.
• 11/20/2025 – Alkermes was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 11/17/2025 – Alkermes had its price target raised by analysts at Truist Financial Corporation from $50.00 to $55.00. They now have a “buy” rating on the stock.
• 11/13/2025 – Alkermes had its price target lowered by analysts at Wells Fargo & Company from $42.00 to $37.00. They now have an “overweight” rating on the stock.
• 11/13/2025 – Alkermes had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $55.00 to $45.00. They now have a “buy” rating on the stock.
• 11/11/2025 – Alkermes is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $50.00 price target on the stock.
• 11/9/2025 – Alkermes was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 11/1/2025 – Alkermes was upgraded by analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating.
• 10/29/2025 – Alkermes had its price target lowered by analysts at Wells Fargo & Company from $44.00 to $42.00. They now have an “overweight” rating on the stock.
• 10/29/2025 – Alkermes had its price target raised by analysts at Needham & Company LLC from $43.00 to $44.00. They now have a “buy” rating on the stock.
• 10/28/2025 – Alkermes was given a new $56.00 price target on by analysts at Jefferies Financial Group Inc.. They now have a “buy” rating on the stock.
• 10/27/2025 – Alkermes had its price target raised by analysts at Mizuho from $40.00 to $45.00. They now have an “outperform” rating on the stock.

Insider Buying and Selling

In other Alkermes news, EVP Craig C. Hopkinson sold 3,748 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $30.00, for a total transaction of $112,440.00. Following the completion of the transaction, the executive vice president owned 65,740 shares in the company, valued at $1,972,200. This trade represents a 5.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 25,748 shares of company stock valued at $786,830. 4.40% of the stock is owned by insiders.

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.